NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

ImmunityBio, Inc. (IBRX) Stock Analysis

ImmunityBio, Inc. (IBRX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

IBRX

$8.08

−$0.11 (−1.34%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IBRX with… →

IBRX Key Statistics

As of Sep 4, 2026
Trading
Open
$8.08
Previous Close
$8.19
Day's Range
8.01–8.24
52-Week Range
1.95–12.43
Volume
4.32M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.14
Valuation
Market Cap
$8.56B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
51.65
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.94
Financials (FY)
Revenue (FY)
$113.29M+668.31%
Net Income (FY)
−$351.40M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.06B
1-Year Return
+238.08%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
10.19M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

IBRX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+308.08%
2025−22.66%
2024−49.00%
2023−0.99%
2022−16.61%
2021−54.39%
2020+251.72%
2019+226.72%
2018−74.16%
2017−21.50%
2016 (partial year)−22.49%

As of September 4, 2026.

IBRX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$113.29M−$351.40M−310.2%
2024$14.75M−$413.56M−2804.8%
2023$622.00K−$583.20M−93761.4%
2022$240.00K−$416.57M−173569.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$113.29M$112.54M−$256.03M−$351.40M−310.2%
2024$14.75M$14.75M−$344.18M−$413.56M−2804.8%
2023$622.00K$622.00K−$361.36M−$583.20M−93761.4%
2022$240.00K$240.00K−$350.62M−$416.57M−173569.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IBRX Valuation vs Biotechnology Median

Median of 656 stocks
MetricIBRXBiotechnology medianvs median
P/S ratio51.6515.263.4x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

ImmunityBio, Inc. (IBRX) carries a market capitalisation of $8.56B. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 684.

The 52-week range on file runs from $1.95 to $12.43. IBRX last closed at $8.08 on September 4, 2026. That is −$0.11 (−1.34%) against the previous close. The latest close sits 314.36% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $113.29M. Against the prior fiscal year total of $14.75M, that is a change of +668.31%. The same year closed with a net loss of $351.40M. The reported profit margin is 0%. Trailing earnings per share are −0.94.

Across the 4 fiscal years on file, revenue moves from $240.00K in 2022 to $113.29M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 51.65. On price-to-sales that is 3.4 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is +238.08%. Across 10 years the annualized return works out at +0.09%. Beta against the wider market is reported at 0.14. Daily returns over the trailing 10 years annualize to a volatility of 111.33%.

Growth & Income

The record shows no dividend for IBRX.

So far in 2026 the price is +308.08%. Across the complete calendar years on file, 2020 returned +251.72% and 2018 returned −74.16%. Of the 9 complete calendar years on file, 2 finished higher.

Peer Comparison

ImmunityBio, Inc. (IBRX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
ImmunityBio, Inc. IBRX $8.56B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. ImmunityBio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About ImmunityBio, Inc.

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Visit website →